日本の精液分析市場：予測（2025年～2032年）

日本の精液分析の市場規模は、予測期間の2025年～2032年に6.61％のCAGRで拡大すると予測されています。2024年の市場規模は6,085万米ドルで、2032年には1億179万米ドルに達する見込みです。

日本の精液分析市場は、不妊に対する意識の高まり、診断技術の進歩、不妊治療クリニックやARTセンターの拡大などを背景に成長するとみられます。

家庭用精液分析キットなど、便利でプライベートな診断ソリューションに対する需要の高まりが、市場の成長をさらに後押しします。しかし、社会文化的な偏見、男性の生殖医療に対する意識の低さ、高額なヘルスケア費用といった課題が、市場の成長を妨げる可能性があります。

日本では、不妊症のかなりの割合が男性要因に起因しており、歴史的には症例の約24%を占めています。夫婦間の不妊治療は広く普及しており、約18.2%が支援を求めています。このことは、男性不妊症に対処するために調整された高度な診断ツールと不妊治療ソリューションに対するニーズが高まっていることを反映しています。

さらに、日本は根深い人口統計学的課題に直面しており、男性の合計特殊出生率は近年、1.92から1.17に低下しています。2020年までに女性の出生率も1人当たり1.4人を下回り、日本におけるリプロダクティブヘルス問題への取り組みの緊急性が浮き彫りになっています。

喫煙や糖尿病などの生活習慣は、日本の男性の出生率に大きな影響を与えます。日本では2022年に推定1,860万人がタバコ使用者となり、タバコ消費量は世界第10位となっています。

喫煙は精液の質の低下に関連しており、人口の13.5%が2型糖尿病または耐糖能障害を患っています。これらの要因から、利用しやすく効果的な男性不妊診断の重要な必要性が浮き彫りになっています。

AIを駆使したイノベーションを含む技術の進歩が、日本の精液分析市場を変革しつつあります。AIを搭載したツールは、数、運動性、形態などの主要な精子パラメーターの正確な評価を提供し、臨床と在宅の両方の環境で信頼できるソリューションを提供します。CASAシステムと高度な画像技術の採用により、診断精度と効率がさらに向上しています。

当レポートでは、日本の精液分析市場について調査し、市場の概要とともに、診断技術別、検査キット・試薬別、年齢層別、エンドユーザー別の動向、競合情勢などをまとめています。

目次

第1章 調査範囲と調査手法

第2章 エグゼクティブサマリー

第3章 市場力学

• 主な促進要因
• 主な抑制要因

第4章 主要な分析

• 親市場分析
• 主要な市場動向
• PESTLE分析
• ポーターのファイブフォース分析
• 成長見通しマッピング
• 市場成熟度分析
• 市場集中分析
• バリューチェーン分析
• 主な購入基準
• 規制枠組み

第5章 診断技術別市場分析

• 顕微鏡検査
• コンピュータ支援精液分析（CASA）
• その他の診断技術

第6章 検査キット・試薬別市場

• 検査キットと消耗品
• 試薬と培地

第7章 年齢層別市場

• 34歳以下
• 35～40歳
• 41歳以上

第8章 エンドユーザー別市場

• 病院
• 不妊治療センター
• 診断検査室
• その他

第9章 競合情勢

• 主要な戦略的展開
• 企業プロファイル
  • BIOMERIEUX SA
  • COOPER COMPANIES INC
  • DITECT CO LTD
  • DNA DIAGNOSTICS CENTER
  • HAMILTON THORNE INC
  • LEJA PRODUCTS BV
  • MEDICAL ELECTRONIC SYSTEMS INC
  • OPTOSCOPIA

LIST OF TABLES

• TABLE 1: MARKET SNAPSHOT - SEMEN ANALYSIS
• TABLE 2: REGULATORY FRAMEWORK
• TABLE 3: JAPAN SEMEN ANALYSIS MARKET, BY DIAGNOSTIC TECHNIQUE, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
• TABLE 4: JAPAN SEMEN ANALYSIS MARKET, BY DIAGNOSTIC TECHNIQUE, FORECAST YEARS, 2025-2032 (IN $ MILLION)
• TABLE 5: JAPAN SEMEN ANALYSIS MARKET, BY TESTING KITS AND REAGENTS, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
• TABLE 6: JAPAN SEMEN ANALYSIS MARKET, BY TESTING KITS AND REAGENTS, FORECAST YEARS, 2025-2032 (IN $ MILLION)
• TABLE 7: JAPAN SEMEN ANALYSIS MARKET, BY AGE GROUP, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
• TABLE 8: JAPAN SEMEN ANALYSIS MARKET, BY AGE GROUP, FORECAST YEARS, 2025-2032 (IN $ MILLION)
• TABLE 9: JAPAN SEMEN ANALYSIS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2023 (IN $ MILLION)
• TABLE 10: JAPAN SEMEN ANALYSIS MARKET, BY END-USER, FORECAST YEARS, 2025-2032 (IN $ MILLION)
• TABLE 11: LIST OF MERGERS & ACQUISITIONS
• TABLE 12: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
• TABLE 13: LIST OF PARTNERSHIPS & AGREEMENTS
• TABLE 14: LIST OF BUSINESS EXPANSIONS AND DIVESTITURES

LIST OF FIGURES

• FIGURE 1: KEY MARKET TRENDS
• FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 3: GROWTH PROSPECT MAPPING FOR JAPAN
• FIGURE 4: MARKET MATURITY ANALYSIS
• FIGURE 5: MARKET CONCENTRATION ANALYSIS
• FIGURE 6: VALUE CHAIN ANALYSIS
• FIGURE 7: KEY BUYING CRITERIA
• FIGURE 8: JAPAN SEMEN ANALYSIS MARKET, GROWTH POTENTIAL, BY DIAGNOSTIC TECHNIQUE, IN 2024
• FIGURE 9: JAPAN SEMEN ANALYSIS MARKET, BY MICROSCOPIC EXAMINATION, 2025-2032 (IN $ MILLION)
• FIGURE 10: JAPAN SEMEN ANALYSIS MARKET, BY COMPUTER-ASSISTED SEMEN ANALYSIS (CASA), 2025-2032 (IN $ MILLION)
• FIGURE 11: JAPAN SEMEN ANALYSIS MARKET, BY OTHER DIAGNOSTIC TECHNIQUES, 2025-2032 (IN $ MILLION)
• FIGURE 12: JAPAN SEMEN ANALYSIS MARKET, GROWTH POTENTIAL, BY TESTING KITS AND REAGENTS, IN 2024
• FIGURE 13: JAPAN SEMEN ANALYSIS MARKET, BY TESTING KITS AND CONSUMABLES, 2025-2032 (IN $ MILLION)
• FIGURE 14: JAPAN SEMEN ANALYSIS MARKET, BY REAGENTS AND MEDIA, 2025-2032 (IN $ MILLION)
• FIGURE 15: JAPAN SEMEN ANALYSIS MARKET, GROWTH POTENTIAL, BY AGE GROUP, IN 2024
• FIGURE 16: JAPAN SEMEN ANALYSIS MARKET, BY 34 YEARS AND BELOW, 2025-2032 (IN $ MILLION)
• FIGURE 17: JAPAN SEMEN ANALYSIS MARKET, BY 35-40 YEARS, 2025-2032 (IN $ MILLION)
• FIGURE 18: JAPAN SEMEN ANALYSIS MARKET, BY 41 YEARS AND ABOVE, 2025-2032 (IN $ MILLION)
• FIGURE 19: JAPAN SEMEN ANALYSIS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2024
• FIGURE 20: JAPAN SEMEN ANALYSIS MARKET, BY HOSPITALS, 2025-2032 (IN $ MILLION)
• FIGURE 21: JAPAN SEMEN ANALYSIS MARKET, BY FERTILITY CENTERS, 2025-2032 (IN $ MILLION)
• FIGURE 22: JAPAN SEMEN ANALYSIS MARKET, BY DIAGNOSTIC LABORATORIES, 2025-2032 (IN $ MILLION)
• FIGURE 23: JAPAN SEMEN ANALYSIS MARKET, BY OTHER END-USERS, 2025-2032 (IN $ MILLION)

KEY FINDINGS

The Japan semen analysis market is predicted to grow with a CAGR of 6.61% over the forecast period 2025-2032. The market was valued at $60.85 million in 2024 and is expected to reach a revenue of $101.79 million by 2032.

The Japan semen analysis market is set to grow, driven by increasing awareness of infertility, advancements in diagnostic technologies, and the expansion of fertility clinics and ART centers.

Rising demand for convenient and private diagnostic solutions, including at-home semen analysis kits, further supports market growth. However, challenges such as sociocultural stigmas, limited awareness of male reproductive health, and high healthcare costs may hinder progress.

MARKET INSIGHTS

A significant percentage of infertility cases in Japan are attributed to male factors, accounting for approximately 24% of cases historically. Infertility treatment among couples is prevalent, with around 18.2% seeking assistance. This reflects the growing need for advanced diagnostic tools and fertility solutions tailored to address male infertility.

Additionally, Japan faces deep-rooted demographic challenges, with the total fertility rate among men declining from 1.92 to 1.17 over recent years. By 2020, the fertility rate for women had also dropped below 1.4 children per woman, highlighting the urgency of addressing reproductive health issues in the nation.

Lifestyle factors such as smoking and diabetes significantly impact male fertility in Japan. An estimated 18.6 million individuals in Japan were tobacco users in 2022, ranking the country as the 10th globally in tobacco consumption.

Smoking has been linked to reduced semen quality, while 13.5% of the population suffers from type 2 diabetes or impaired glucose tolerance, conditions known to adversely affect sperm quality and quantity. These factors highlight the critical need for accessible and effective male fertility diagnostics.

Technological advancements, including AI-driven innovations, are transforming the semen analysis market in Japan. AI-powered tools provide precise assessments of key sperm parameters, such as count, motility, and morphology, offering reliable solutions in both clinical and home-based settings. The adoption of CASA systems and advanced imaging techniques is further enhancing diagnostic accuracy and efficiency.

SEGMENTATION ANALYSIS

The Japan semen analysis market is segmented into diagnostic technique, testing kits and reagents, age group, and end-user. The diagnostic technique category is further classified into microscopic examination, computer-assisted semen analysis (CASA), and other diagnostic techniques.

CASA systems are gaining traction in fertility clinics and laboratories for their ability to deliver automated and consistent analyses. The rising demand for at-home testing kits reflects a shift toward patient-centered solutions, driven by convenience and privacy.

On the other hand, microscopic examination remains a widely used method for semen analysis in clinical settings, valued for its cost-effectiveness and ability to meet fundamental diagnostic needs.

However, advanced technologies, particularly those integrating AI, are increasingly being adopted to address limitations in traditional techniques and to provide standardized results. These innovations align with the growing demand for accurate and accessible diagnostics.

With a high prevalence of male infertility, lifestyle-related health conditions, and demographic challenges, the demand for advanced reproductive health solutions in Japan is expected to rise. Addressing barriers to awareness and accessibility, alongside the continued integration of innovative technologies, positions Japan as a key market for the development of semen analysis and fertility diagnostics.

COMPETITIVE INSIGHTS

Some of the leading players in the Japan semen analysis market include bioMerieux SA, Optoscopia, Ditect Co Ltd, DNA Diagnostics Center, Hamilton Thorne Inc, etc.

Optoscopia is a leading manufacturer of computer-aided semen analysis (CASA) systems, specializing in the integration of optical technology and artificial intelligence (AI) to meticulously examine sperm samples.

The company's flagship products, the SIA Lab and SIA Lab Plus are designed to process semen samples with high accuracy, assessing essential parameters related to sperm quality, including motility, concentration, vitality, morphology, leukocyte presence, and DNA fragmentation. The company operates through 2 primary locations in Spain and Tunisia.

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

• 1.1. STUDY OBJECTIVES
• 1.2. METHODOLOGY
• 1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

• 2.1. MARKET SIZE & ESTIMATES
• 2.2. COUNTRY SNAPSHOT
• 2.3. COUNTRY ANALYSIS
• 2.4. SCOPE OF STUDY
• 2.5. CRISIS SCENARIO ANALYSIS
• 2.6. MAJOR MARKET FINDINGS
  • 2.6.1. INCREASING PREFERENCE FOR HOME SEMEN ANALYSIS KITS DUE TO CONVENIENCE AND PRIVACY
  • 2.6.2. INTEGRATION OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

3. MARKET DYNAMICS

• 3.1. KEY DRIVERS
  • 3.1.1. INCREASING INCIDENCE OF MALE INFERTILITY IN JAPAN
  • 3.1.2. ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES
  • 3.1.3. EXPANSION OF FERTILITY CLINICS AND ART CENTERS
  • 3.1.4. GROWING AWARENESS OF REPRODUCTIVE HEALTH
• 3.2. KEY RESTRAINTS
  • 3.2.1. HIGH COSTS OF ADVANCED DIAGNOSTIC PROCEDURES
  • 3.2.2. SOCIOCULTURAL STIGMAS ASSOCIATED WITH MALE INFERTILITY
  • 3.2.3. INCONSISTENT INSURANCE COVERAGE AND REIMBURSEMENT POLICIES

4. KEY ANALYTICS

• 4.1. PARENT MARKET ANALYSIS
• 4.2. KEY MARKET TRENDS
  • 4.2.1. INCREASING DEMAND FOR CONVENIENT AND PRIVATE HOME-BASED SEMEN TESTING KITS
• 4.3. PESTLE ANALYSIS
  • 4.3.1. POLITICAL
  • 4.3.2. ECONOMICAL
  • 4.3.3. SOCIAL
  • 4.3.4. TECHNOLOGICAL
  • 4.3.5. LEGAL
  • 4.3.6. ENVIRONMENTAL
• 4.4. PORTER'S FIVE FORCES ANALYSIS
  • 4.4.1. BUYERS POWER
  • 4.4.2. SUPPLIERS POWER
  • 4.4.3. SUBSTITUTION
  • 4.4.4. NEW ENTRANTS
  • 4.4.5. INDUSTRY RIVALRY
• 4.5. GROWTH PROSPECT MAPPING
  • 4.5.1. GROWTH PROSPECT MAPPING FOR JAPAN
• 4.6. MARKET MATURITY ANALYSIS
• 4.7. MARKET CONCENTRATION ANALYSIS
• 4.8. VALUE CHAIN ANALYSIS
  • 4.8.1. EQUIPMENT AND REAGENT MANUFACTURERS
  • 4.8.2. DISTRIBUTORS AND SUPPLIERS
  • 4.8.3. SERVICE PROVIDERS
  • 4.8.4. END-USER
• 4.9. KEY BUYING CRITERIA
  • 4.9.1. ACCURACY AND RELIABILITY
  • 4.9.2. EASE OF USE
  • 4.9.3. COST
  • 4.9.4. TURNAROUND TIME
  • 4.9.5. PORTABILITY AND CONVENIENCE
• 4.10. REGULATORY FRAMEWORK

5. MARKET BY DIAGNOSTIC TECHNIQUE

• 5.1. MICROSCOPIC EXAMINATION
  • 5.1.1. MARKET FORECAST FIGURE
  • 5.1.2. SEGMENT ANALYSIS
• 5.2. COMPUTER-ASSISTED SEMEN ANALYSIS (CASA)
  • 5.2.1. MARKET FORECAST FIGURE
  • 5.2.2. SEGMENT ANALYSIS
• 5.3. OTHER DIAGNOSTIC TECHNIQUES
  • 5.3.1. MARKET FORECAST FIGURE
  • 5.3.2. SEGMENT ANALYSIS

6. MARKET BY TESTING KITS AND REAGENTS

• 6.1. TESTING KITS AND CONSUMABLES
  • 6.1.1. MARKET FORECAST FIGURE
  • 6.1.2. SEGMENT ANALYSIS
• 6.2. REAGENTS AND MEDIA
  • 6.2.1. MARKET FORECAST FIGURE
  • 6.2.2. SEGMENT ANALYSIS

7. MARKET BY AGE GROUP

• 7.1. 34 YEARS AND BELOW
  • 7.1.1. MARKET FORECAST FIGURE
  • 7.1.2. SEGMENT ANALYSIS
• 7.2. 35-40 YEARS
  • 7.2.1. MARKET FORECAST FIGURE
  • 7.2.2. SEGMENT ANALYSIS
• 7.3. 41 YEARS AND ABOVE
  • 7.3.1. MARKET FORECAST FIGURE
  • 7.3.2. SEGMENT ANALYSIS

8. MARKET BY END-USER

• 8.1. HOSPITALS
  • 8.1.1. MARKET FORECAST FIGURE
  • 8.1.2. SEGMENT ANALYSIS
• 8.2. FERTILITY CENTERS
  • 8.2.1. MARKET FORECAST FIGURE
  • 8.2.2. SEGMENT ANALYSIS
• 8.3. DIAGNOSTIC LABORATORIES
  • 8.3.1. MARKET FORECAST FIGURE
  • 8.3.2. SEGMENT ANALYSIS
• 8.4. OTHER END-USERS
  • 8.4.1. MARKET FORECAST FIGURE
  • 8.4.2. SEGMENT ANALYSIS

9. COMPETITIVE LANDSCAPE

• 9.1. KEY STRATEGIC DEVELOPMENTS
  • 9.1.1. MERGERS & ACQUISITIONS
  • 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
  • 9.1.3. PARTNERSHIPS & AGREEMENTS
  • 9.1.4. BUSINESS EXPANSIONS AND DIVESTITURES
• 9.2. COMPANY PROFILES
  • 9.2.1. BIOMERIEUX SA
    • 9.2.1.1. COMPANY OVERVIEW
    • 9.2.1.2. PRODUCTS
    • 9.2.1.3. STRENGTHS & CHALLENGES
  • 9.2.2. COOPER COMPANIES INC
    • 9.2.2.1. COMPANY OVERVIEW
    • 9.2.2.2. PRODUCTS
    • 9.2.2.3. STRENGTHS & CHALLENGES
  • 9.2.3. DITECT CO LTD
    • 9.2.3.1. COMPANY OVERVIEW
    • 9.2.3.2. PRODUCTS
    • 9.2.3.3. STRENGTHS & CHALLENGES
  • 9.2.4. DNA DIAGNOSTICS CENTER
    • 9.2.4.1. COMPANY OVERVIEW
    • 9.2.4.2. PRODUCTS
    • 9.2.4.3. STRENGTHS & CHALLENGES
  • 9.2.5. HAMILTON THORNE INC
    • 9.2.5.1. COMPANY OVERVIEW
    • 9.2.5.2. PRODUCTS
    • 9.2.5.3. STRENGTHS & CHALLENGES
  • 9.2.6. LEJA PRODUCTS BV
    • 9.2.6.1. COMPANY OVERVIEW
    • 9.2.6.2. PRODUCTS
    • 9.2.6.3. STRENGTHS & CHALLENGES
  • 9.2.7. MEDICAL ELECTRONIC SYSTEMS INC
    • 9.2.7.1. COMPANY OVERVIEW
    • 9.2.7.2. PRODUCTS
    • 9.2.7.3. STRENGTHS & CHALLENGES
  • 9.2.8. OPTOSCOPIA
    • 9.2.8.1. COMPANY OVERVIEW
    • 9.2.8.2. PRODUCTS
    • 9.2.8.3. STRENGTHS & CHALLENGES